Crinetics Pharmaceuticals (CRNX)
Develops oral GPCR medicines for endocrine diseases and endocrine-related tumors.
$84.95
0.00 (0.00%)
Delisted · Sep 2, 2026
Something off on this page? Send us feedback.
Next report
Nov 5, 26
in 43 days
EPS estimate
−$1.20
Revenue estimate
$21.0M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported−$0.88−$1.04−$1.23−$1.38−$1.29−$1.23−$1.14Pending
Estimate−$0.92−$0.99−$1.13−$1.27−$1.37−$1.22−$1.18−$1.20
Surprise+4.3%−5.1%−8.8%−8.7%+5.8%−0.8%+3.4%—
RevenueReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported—$361.0K$1.0M$143.0K$6.2M$10.7M$25.1MPending
Estimate$727.3K$347.9K$394.0K$4.3M$4.5M$8.5M$14.8M$21.0M
Surprise—+3.8%+161.7%−96.7%+37.2%+26.1%+69.2%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | −$0.89 | — | — |
| Sep 2027 | −$0.96 | — | — |
| Jun 2027 | −$1.00 | — | — |
| Mar 2027 | −$1.06 | — | — |
| Dec 2026 | −$1.15 | — | — |
| Nov 2026 | −$1.20 | — | — |
| Aug 2026 | −$1.18 | −$1.14 | +3.4% |
| May 2026 | −$1.22 | −$1.23 | −0.8% |
| Feb 2026 | −$1.37 | −$1.29 | +5.8% |
| Nov 2025 | −$1.27 | −$1.38 | −8.7% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| Jul 2018 | |||
| Dec 2017 | |||
| Sep 2017 | |||
| Jun 2017 | |||
| Mar 2017 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | −$0.89 | — | — | $56.3M | — | — | — |
| Sep 2027 | −$0.96 | — | — | $49.7M | — | — | — |
| Jun 2027 | −$1.00 | — | — | $40.2M | — | — | — |
| Mar 2027 | −$1.06 | — | — | $27.2M | — | — | — |
| Dec 2026 | −$1.15 | — | — | $24.1M | — | — | — |
| Nov 5, 2026 | −$1.20 | — | — | $21.0M | — | — | — |
| Aug 3, 2026 | −$1.18 | −$1.14 | +3.4% | $14.8M | $25.1M | +69.2% | +0.1% |
| May 7, 2026 | −$1.22 | −$1.23 | −0.8% | $8.5M | $10.7M | +26.1% | −13.8% |
| Feb 26, 2026 | −$1.37 | −$1.29 | +5.8% | $4.5M | $6.2M | +37.2% | −6.0% |
| Nov 6, 2025 | −$1.27 | −$1.38 | −8.7% | $4.3M | $143.0K | −96.7% | −8.0% |
| Aug 7, 2025 | |||||||
| May 8, 2025 | |||||||
| Feb 27, 2025 | |||||||
| Nov 12, 2024 | |||||||
| Aug 8, 2024 | |||||||
| May 9, 2024 | |||||||
| Feb 28, 2024 | |||||||
| Nov 7, 2023 | |||||||
| Aug 8, 2023 | |||||||
| May 4, 2023 | |||||||
| Feb 28, 2023 | |||||||
| Nov 14, 2022 | |||||||
| Aug 12, 2022 | |||||||
| May 12, 2022 | |||||||
| Mar 30, 2022 | |||||||
| Nov 5, 2021 | |||||||
| Aug 10, 2021 | |||||||
| May 6, 2021 | |||||||
| Mar 30, 2021 | |||||||
| Nov 6, 2020 | |||||||
| Aug 7, 2020 | |||||||
| May 8, 2020 | |||||||
| Mar 9, 2020 | |||||||
| Nov 12, 2019 | |||||||
| Aug 13, 2019 | |||||||
| May 13, 2019 | |||||||
| Mar 13, 2019 | |||||||
| Nov 13, 2018 | |||||||
| Aug 30, 2018 | |||||||
| Jul 18, 2018 | |||||||
| Dec 31, 2017 | |||||||
| Sep 30, 2017 | |||||||
| Jun 30, 2017 | |||||||
| Mar 31, 2017 |